Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5360197

CCN(C(C)C)C(C)C.O=C(O)C(F)(F)F

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
DPP8 Q6V1X1 3/20 0.33
DPP7 Q9UHL4 2/20 0.33
DPP4 P27487 1/20 0.33
MLYCD O95822 3/20 0.32
FAAH O00519 5/20 0.31
MAPT P10636 1/20 0.31
ALDH1A1 P00352 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CES1 P23141 3/20 0.30
CES2 O00748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pivalate SCHEMBL1831109 0.84 TSHR (0.33) CHRM2CHRM1CHRM3MAPTALDH1A1
Bicarbonate SCHEMBL27506741 0.83 FFAR3 (0.35) CHRM1CHRM3
Acetic Acid SCHEMBL1033681 0.80 FFAR3 (0.39) CHRM2CHRM4CHRM5CHRM1CHRM3
Carbamic Acid SCHEMBL28872525 0.78 ACHE (0.37)
Propionic Acid SCHEMBL27829635 0.78 FFAR3 (0.53) ALDH1A1
Trifluoromethanesulfonic Acid SCHEMBL628113 0.77 EPHX1 (0.31) ALDH1A1L3MBTL1
Trifluoroacetic Acid SCHEMBL3708677 0.75 MLYCD (0.36) CHRM2CHRM4CHRM5CHRM1CHRM3
Trifluoroacetic Acid SCHEMBL17396033 0.75 CHRM2 (0.38) CHRM2CHRM4CHRM5CHRM1CHRM3
Trifluoroacetic Acid SCHEMBL726303 0.75 MLYCD (0.36) CHRM2CHRM4CHRM5CHRM1CHRM3
Trifluoroacetic Acid SCHEMBL3708678 0.75 MLYCD (0.36) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100379709-C Process for preparing phosphitylated compounds HONEYWELL INT INC (US) 2008-04-09 CN claimed
CN-1646452-A Process for preparing phosphitylated compounds HONEYWELL INT INC (US) 2005-07-27 CN claimed
US-6894158-B2 Methods of producing phosphitylated compounds HONEYWELL INTERNATIONAL INC. (US) 2005-05-17 US claimed
EP-1476407-A2 METHODS OF PRODUCING PHOSPHITYLATED COMPOUNDS Honeywell International Inc. (US) 2004-11-17 EP claimed
US-20030232980-A1 Methods of producing phosphitylated compounds HONEYWELL INTERNATIONAL INC. 2003-12-18 US claimed
WO-2003072586-A2 METHODS OF PRODUCING PHOSPHITYLATED COMPOUNDS HONEYWELL INTERNATIONAL INC. (US) 2003-09-04 WO claimed
CN-108472381-B Compounds and therapeutic uses thereof 森陶里治疗有限公司 2023-06-06 CN disclosed
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2021-12-02 US disclosed
US-10953100-B2 Compounds and therapeutic uses thereof CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2021-03-23 US disclosed
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2018-10-04 US disclosed
CN-108472381-A COMPOUNDS AND THERAPEUTIC USES THEREOF 森陶里治疗有限公司 2018-08-31 CN disclosed
WO-2017060729-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTAURI THERAPEUTICS LIMITED (GB) 2017-04-13 WO disclosed
EP-2864308-B1 (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues UNIV BRISTOL (GB) 2016-10-19 EP disclosed
US-20030232980-A1 Methods of producing phosphitylated compounds HONEYWELL INTERNATIONAL INC. 2003-12-18 US disclosed
WO-2003072586-A2 METHODS OF PRODUCING PHOSPHITYLATED COMPOUNDS HONEYWELL INTERNATIONAL INC. (US) 2003-09-04 WO disclosed
EP-0882041-B1 PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2003-03-26 EP disclosed
US-6069145-A AGAINST ANTIBIOTIC RESISTANT BACTERIA ZENECA LIMITED (GB) 2000-05-30 US disclosed
EP-0882041-A1 PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS AstraZeneca AB (SE) 1998-12-09 EP disclosed
WO-1997027188-A1 PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ZENECA LIMITED (GB) 1997-07-31 WO disclosed
US-3944538-A Process and apparatus for the synthesis of peptides not linked to polymers BODANSZKY MIKLOS 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 CHRM2 4527/4885CHRM4 4479/4885CHRM5 4402/4885
US-10953100-B2 Compounds and therapeutic uses thereof CD47, MYD88, NFATC1 CHRM2 4527/4885CHRM4 4479/4885CHRM5 4402/4885
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 CHRM2 4527/4885CHRM4 4479/4885CHRM5 4402/4885
US-20030232980-A1 Methods of producing phosphitylated compounds PHOSPHO1, INPPL1, PLCG1 CHRM2 2495/4885CHRM4 2806/4885CHRM5 2326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.